166 related articles for article (PubMed ID: 7543822)
1. In vitro and in vivo antitumor activity of a chimeric anti-CD19 antibody.
Pietersz GA; Wenjun L; Sutton VR; Burgess J; McKenzie IF; Zola H; Trapani JA
Cancer Immunol Immunother; 1995 Jul; 41(1):53-60. PubMed ID: 7543822
[TBL] [Abstract][Full Text] [Related]
2. Preclinical investigation of the antitumour effects of anti-CD19-idarubicin immunoconjugates.
Rowland AJ; Pietersz GA; McKenzie IF
Cancer Immunol Immunother; 1993 Aug; 37(3):195-202. PubMed ID: 7687521
[TBL] [Abstract][Full Text] [Related]
3. Chimeric (mouse/human) anti-colon cancer antibody c30.6 inhibits the growth of human colorectal cancer xenografts in scid/scid mice.
Mount PF; Sutton VR; Li W; Burgess J; McKEnzie IF; Pietersz GA; Trapani JA
Cancer Res; 1994 Dec; 54(23):6160-6. PubMed ID: 7954462
[TBL] [Abstract][Full Text] [Related]
4. Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19.
Vlasveld LT; Hekman A; Vyth-Dreese FA; Melief CJ; Sein JJ; Voordouw AC; Dellemijn TA; Rankin EM
Cancer Immunol Immunother; 1995 Jan; 40(1):37-47. PubMed ID: 7530170
[TBL] [Abstract][Full Text] [Related]
5. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
6. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin.
Ghetie MA; Tucker K; Richardson J; Uhr JW; Vitetta ES
Blood; 1992 Nov; 80(9):2315-20. PubMed ID: 1384801
[TBL] [Abstract][Full Text] [Related]
7. [Optimization of CD19 chimeric antigen receptor T cell establishment and observation of the killing effect in vitro and in vivo].
Ren CX; Chen XX; Zhao L; Tian Y; Xu KL; Zhao K
Zhonghua Xue Ye Xue Za Zhi; 2022 Jun; 43(6):506-512. PubMed ID: 35968595
[No Abstract] [Full Text] [Related]
8. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA
Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284
[TBL] [Abstract][Full Text] [Related]
9. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.
Reff ME; Carner K; Chambers KS; Chinn PC; Leonard JE; Raab R; Newman RA; Hanna N; Anderson DR
Blood; 1994 Jan; 83(2):435-45. PubMed ID: 7506951
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G
Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562
[TBL] [Abstract][Full Text] [Related]
11. Preparation and characterization of a chimeric CD19 monoclonal antibody.
Zola H; MacArdle PJ; Bradford T; Weedon H; Yasui H; Kurosawa Y
Immunol Cell Biol; 1991 Dec; 69 ( Pt 6)():411-22. PubMed ID: 1725979
[TBL] [Abstract][Full Text] [Related]
12. Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model.
Hooijberg E; van den Berk PC; Sein JJ; Wijdenes J; Hart AA; de Boer RW; Melief CJ; Hekman A
Cancer Res; 1995 Feb; 55(4):840-6. PubMed ID: 7531616
[TBL] [Abstract][Full Text] [Related]
13. A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies.
Gidlöf C; Dohlsten M; Lando P; Kalland T; Sundström C; Tötterman TH
Blood; 1997 Mar; 89(6):2089-97. PubMed ID: 9058731
[TBL] [Abstract][Full Text] [Related]
14. Antitumour activity of a chimeric antibody against the leucocyte antigen CD48.
Sun H; Biggs JC; Smith GM
Cancer Immunol Immunother; 2000 Jan; 48(10):595-602. PubMed ID: 10630312
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest.
Ghetie MA; Picker LJ; Richardson JA; Tucker K; Uhr JW; Vitetta ES
Blood; 1994 Mar; 83(5):1329-36. PubMed ID: 7509655
[TBL] [Abstract][Full Text] [Related]
16. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma.
Vallera DA; Todhunter DA; Kuroki DW; Shu Y; Sicheneder A; Chen H
Clin Cancer Res; 2005 May; 11(10):3879-88. PubMed ID: 15897589
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
Lopes de Menezes DE; Pilarski LM; Allen TM
Cancer Res; 1998 Aug; 58(15):3320-30. PubMed ID: 9699662
[TBL] [Abstract][Full Text] [Related]
18. Structure and domain organization of the CD19 antigen of human, mouse, and guinea pig B lymphocytes. Conservation of the extensive cytoplasmic domain.
Zhou LJ; Ord DC; Hughes AL; Tedder TF
J Immunol; 1991 Aug; 147(4):1424-32. PubMed ID: 1714482
[TBL] [Abstract][Full Text] [Related]
19. Killing of autologous B-lineage malignancy using CD3 x CD19 bispecific monoclonal antibody in end stage leukemia and lymphoma.
Haagen IA; Geerars AJ; de Lau WB; Clark MR; van de Griend RJ; Bast BJ; de Gast BC
Blood; 1994 Jul; 84(2):556-63. PubMed ID: 7517719
[TBL] [Abstract][Full Text] [Related]
20. Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model.
Vuist WM; v Buitenen F; de Rie MA; Hekman A; Rümke P; Melief CJ
Cancer Res; 1989 Jul; 49(14):3783-8. PubMed ID: 2472198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]